Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-08-2015 | Original Article

¹⁸F-FDG PET/CT in inflammation of unknown origin: a cost-effectiveness pilot-study

Authors: H. Balink, S. S. Tan, N. J. G. M. Veeger, F. Holleman, B. L. F. van Eck-Smit, R. J. Bennink, H. J. Verberne

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2015

Abstract

Purpose

Patients with increased inflammatory parameters, nonspecific signs and symptoms without fever and without a diagnosis after a variety of diagnostic procedures are a diagnostic dilemma and are referred to as having inflammation of unknown origin (IUO). The objective of this pilot study was to compare the cost-effectiveness of a diagnostic work-up/strategy with and without ¹⁸F-FDG PET/CT in patients with IUO using a published dataset as a reference.

Methods

IUO patients without ¹⁸F-FDG PET/CT (group A, 46 patients) and IUO patients referred for ¹⁸F-FDG PET/CT (group B, 46 patients) were selected. IUO was defined as the combination of nonspecific signs and symptoms and a prolonged erythrocyte sedimentation rate (ESR), defined as ≥age/2 in men and ≥(age + 10)/2 in women (ESR in millimetres per hour and age in years), and/or C-reactive protein (CRP) ≥15 mg/l. The costs of all tests and procedures and the number of hospitalization days in each patient to reach a diagnosis were calculated using current Dutch tariffs.

Results

In group A a diagnosis was reached in 14 of the 46 patients. The mean cost per patient of all the diagnostic procedures was €2,051, and including the cost of hospitalization was €12,614. In group B a diagnosis was reached in 32 of the 46 patients. The mean cost per patient of all the diagnostic procedures was €1,821, significantly lower than in group A (p < 0.0002), and including the cost of hospitalization was €5,298.

Conclusion

In IUO ¹⁸F-FDG PET/CT has the potential to become a cost-effective routine imaging technique indicating the direction for further diagnostic decisions thereby allowing unnecessary, invasive and expensive diagnostic investigations to be avoided and possibly the duration of hospitalization to be reduced. However, a prospective multicentre “bottom-up microcosting” cost-effectiveness study is warranted before these preliminary data can be extrapolated to clinical practice.

Vanderschueren S, Del Biondo E, Ruttens D, Van Boxelaer I, Wauters E, Knockaert DD. Inflammation of unknown origin versus fever of unknown origin: two of a kind. Eur J Intern Med. 2009;20:415–8. doi:10.1016/j.ejim.2009.01.002.PubMedCrossRef

Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–35. doi:10.1038/nature07201.PubMedCrossRef

Glaudemans AW, de Vries EF, Galli F, Dierckx RA, Slart RH, Signore A. The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013;2013:623036. doi:10.1155/2013/623036.PubMedCentralPubMedCrossRef

Hooisma GA, Balink H, Houtman PM, Slart RH, Lensen KD. Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study. Clin Rheumatol. 2012;31:861–71. doi:10.1007/s10067-012-1945-0.PubMedCrossRef

Lensen KJ, Voskuyl AE, van der Laken CJ, Comans EF, van Schaardenburg D, Arntzenius AB, et al. 18F-fluorodeoxyglucose positron emission tomography in elderly patients with an elevated erythrocyte sedimentation rate of unknown origin. PLoS One. 2013;8:e58917. doi:10.1371/journal.pone.0058917.PubMedCentralPubMedCrossRef

Balink H, Bennink RJ, Veeger NJ, van Eck-Smit BL, Verberne HJ. Diagnostic utility of (18)F-FDG PET/CT in inflammation of unknown origin. Clin Nucl Med. 2014;39:419–25. doi:10.1097/RLU.0000000000000423.PubMedCrossRef

Jasper N, Dabritz J, Frosch M, Loeffler M, Weckesser M, Foell D. Diagnostic value of [(18)F]-FDG PET/CT in children with fever of unknown origin or unexplained signs of inflammation. Eur J Nucl Med Mol Imaging. 2010;37:136–45.PubMedCrossRef

Bleeker-Rovers CP, Vos FJ, de Kleijn EM, Mudde AH, Dofferhoff TS, Richter C, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore). 2007;86:26–38.CrossRef

Perrin AE, Goichot B, Andres E, Grunenberger F, Wicky C, Ruellan A, et al. Development and long-term prognosis of unexplained persistent inflammatory biologic syndromes. Rev Med Interne. 2002;23:683–9.PubMedCrossRef

10.

Tan SS, Bouwmans CA, Rutten FF, Hakkaart-van RL. Update of the Dutch Manual for Costing in Economic Evaluations. Int J Technol Assess Health Care. 2012;28:152–8. doi:10.1017/S0266462312000062.PubMedCrossRef

11.

Balink H, Collins J, Bruyn GA, Gemmel F. F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Clin Nucl Med. 2009;34:862–8. doi:10.1097/RLU.0b013e3181becfb1.PubMedCrossRef

12.

Hot A, Jaisson I, Girard C, French M, Durand DV, Rousset H, et al. Yield of bone marrow examination in diagnosing the source of fever of unknown origin. Arch Intern Med. 2009;169:2018–23. doi:10.1001/archinternmed.2009.401.PubMedCrossRef

13.

Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.PubMedCrossRef

14.

Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–80.PubMedCrossRef

15.

Becerra Nakayo EM, Garcia Vicente AM, Soriano Castrejon AM, Mendoza Narvaez JA, Talavera Rubio MP, Poblete Garcia VM, et al. Analysis of cost-effectiveness in the diagnosis of fever of unknown origin and the role of (18)F-FDG PET-CT: a proposal of diagnostic algorithm. Rev Esp Med Nucl Imagen Mol. 2012;31:178–86.PubMed

16.

Swindle R, Lukas CV, Meyer DA, Barnett PG, Hendricks AM. Cost analysis in the Department of Veterans Affairs: consensus and future directions. Med Care. 1999;37(4 Suppl Va):AS3–8.PubMed

17.

Wordsworth S, Ludbrook A, Caskey F, Macleod A. Collecting unit cost data in multicentre studies. Creating comparable methods. Eur J Health Econ. 2005;6:38–44. doi:10.1007/s10198-004-0259-9.PubMedCrossRef

18.

Tan SS, Rutten FF, van Ineveld BM, Redekop WK, Hakkaart-van RL. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ. 2009;10:39–45. doi:10.1007/s10198-008-0101-x.PubMedCrossRef

19.

Rutledge TL. Advances in surgical care. Obstet Gynecol Clin North Am. 2012;39:145–63. doi:10.1016/j.ogc.2012.02.005.PubMedCrossRef

20.

Sibbald M, Cavalcanti RB. The biasing effect of clinical history on physical examination diagnostic accuracy. Med Educ. 2011;45:827–34. doi:10.1111/j.1365-2923.2011.03997.x.PubMedCrossRef

Title: 18F-FDG PET/CT in inflammation of unknown origin: a cost-effectiveness pilot-study
Authors: H. Balink
S. S. Tan
N. J. G. M. Veeger
F. Holleman
B. L. F. van Eck-Smit
R. J. Bennink
H. J. Verberne
Publication date: 01-08-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3010-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-FDG PET/CT in inflammation of unknown origin: a cost-effectiveness pilot-study

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2015

PET/MR brain imaging: evaluation of clinical UTE-based attenuation correction

Quantifying [18F]fluorodeoxyglucose uptake in the arterial wall: the effects of dual time-point imaging and partial volume effect correction

Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis

68Ga-PSMA imaging of metastatic breast cancer

Adding variables to complexity. Molecular imaging and molecular biology: a no-longer-secret liaison in NETs

Aortic 18F-FDG uptake in patients suffering from granulomatosis with polyangiitis